Real-time monitoring across 40+ data sources

Stop finding out about competitor moves after everyone else

PharmaPulse tracks regulatory filings, trial updates, pipeline announcements, and commercial moves across every major market. Automatically. So you never get caught off guard again.

See what we track

Monitoring data from

FDA EMA ClinicalTrials.gov EU CTR PMDA Health Canada PubMed SEC Filings
FDA Approval: Rybrevant + lazertinib NSCLC combination approved
Phase III Readout: BMS nivolumab KEYNOTE-671 OS data released
Trial Update: Pfizer ATTR-ACT-2 enrollment complete, Q3 readout expected
Pipeline Move: AstraZeneca discontinues tezepelumab pediatric program
EMA Decision: Novartis iscalimab MAA validated, review clock started
Deal: Merck licenses oral GLP-1 candidate from Hansoh for $1.9B
Commercial: Lilly expanding Zepbound sales force by 400 reps across EU
Publication: Roche tiragolumab Phase III data in NEJM, primary endpoint missed
FDA Approval: Rybrevant + lazertinib NSCLC combination approved
Phase III Readout: BMS nivolumab KEYNOTE-671 OS data released
Trial Update: Pfizer ATTR-ACT-2 enrollment complete, Q3 readout expected
Pipeline Move: AstraZeneca discontinues tezepelumab pediatric program
EMA Decision: Novartis iscalimab MAA validated, review clock started
Deal: Merck licenses oral GLP-1 candidate from Hansoh for $1.9B
Commercial: Lilly expanding Zepbound sales force by 400 reps across EU
Publication: Roche tiragolumab Phase III data in NEJM, primary endpoint missed
Coverage

Every signal that matters. Nothing that doesn't.

PharmaPulse pulls from regulatory databases, trial registries, company filings, scientific journals, and commercial intelligence feeds.

🏛️

Regulatory Decisions

FDA approvals, Complete Response Letters, EMA opinions, Health Canada decisions, MHRA actions. Every major agency, globally.

🧬

Clinical Trial Activity

New registrations, phase transitions, enrollment milestones, protocol amendments, and completion date changes across ClinicalTrials.gov and EU CTR.

📋

Submissions and Filings

BLA, NDA, sNDA, MAA, and supplemental submissions. PDUFA dates. Advisory committee announcements. Label updates.

📰

Publications and Data

Major journal publications, NEJM and Lancet readouts, preprint releases, label expansions, and key data presentations.

💼

Pipeline and Strategy

In-licensing deals, asset acquisitions, program discontinuations, indication expansions, and strategic partnership announcements.

🏢

Commercial Intelligence

Field force changes, formulary wins, market access updates, earnings call highlights, and leadership appointments tied to key programs.

Live Feed

What PharmaPulse looks like in practice

Real signal types from our monitoring system. The kind of thing that lands in your inbox before anyone on your team has seen it.

Live
Your PharmaPulse feed — Oncology / Immunology
Approval
FDA approves J&J amivantamab plus lazertinib for EGFR-mutated NSCLC Accelerated approval granted for patients who progressed on osimertinib. First chemo-free combo in this setting. Direct competitive pressure on AstraZeneca Tagrisso.
4m ago
Trial
Roche SKYSCRAPER-08 Phase III enrollment complete Tiragolumab plus atezolizumab in 1L NSCLC hit 950 patients. Primary completion estimated Q4 2026. Previous Phase II showed mixed results. Data still expected.
31m ago
Filing
Novartis submits MAA for iscalimab in autoimmune indications EMA accepted application across three autoimmune indications simultaneously. Broad label strategy. CHMP review clock starts April 2026. Decision expected Q1 2027.
2h ago
Commercial
Lilly posting 340 new Mounjaro field roles across Germany, France, Spain Job postings concentrated in endocrinology and primary care. Pattern consistent with pre-formulary negotiation positioning. T2D market defense signal.
5h ago
How it works

Set up in two minutes. Runs on its own.

No onboarding calls. No professional services. No 90-day implementation. You tell us what you're watching and we start immediately.

🎯

Tell us your focus

Enter the drugs, companies, or disease areas you monitor. Add geographic markets if relevant. Takes about two minutes.

We scan everything

PharmaPulse continuously monitors 40+ data sources across regulators, trial registries, scientific journals, financial filings, and more.

📬

You get the signal

Alerts land in your inbox with context built in. Not just the news but what it means, why it matters, and what your competitors might do next.

Pricing

Start free. No contracts.

Cancel any time. No onboarding fees. No annual commitments unless you want one.

Free
$0/mo
For individuals who want to stay informed on one competitor.
  • + 1 drug or company tracked
  • + Regulatory and trial signals
  • + Weekly digest email
  • - Real-time alerts
  • - Commercial intelligence
  • - "So what" AI context
  • - Team access
Get started free
Most popular
Pro
$99/mo
For CI analysts who need full coverage on a competitive set.
  • + Up to 10 drugs or companies
  • + All 6 signal types
  • + Real-time alerts
  • + Commercial intelligence
  • + "So what" AI context on every signal
  • + Daily digest option
  • - Team seats
Start 14-day free trial
Team
$299/mo
For CI teams tracking a full portfolio across multiple TAs.
  • + Unlimited tracking
  • + All 6 signal types
  • + Real-time alerts
  • + Commercial intelligence
  • + "So what" AI context + analysis
  • + Up to 5 team seats
  • + Slack or Teams integration
Start 14-day free trial
Why PharmaPulse

Most teams find out too late

Without PharmaPulse
  • Manually scanning FDA.gov, EMA, and trial registries every week
  • Finding out about competitor filings from the trade press
  • Piecing together signals from six different tools
  • Briefing leadership after the fact
  • Missing label expansions until they show up in a formulary
With PharmaPulse
  • All signals consolidated in one daily digest
  • Alerts within hours of a filing, not days
  • Context built in — not just the news, but what it means
  • Brief your team before they ask
  • Nothing slips through

Your competitors are moving. You should know about it.

Start monitoring for free. No credit card. Signals start within minutes of setup.

No spam. No sales calls. Unsubscribe any time.